Skip to main content

Market Overview

Amgen Reveals Post-Hoc Data For Its KRAS Inhibitor In Lung Cancer Patients

Amgen Reveals Post-Hoc Data For Its KRAS Inhibitor In Lung Cancer Patients
  • Amgen Inc (NASDAQ: AMGNannounced results from two analyses of the Phase 2 CodeBreaK 100 trial evaluating Lumakras (sotorasib). 
  • Lumakras, a KRASG12C inhibitor, is approved in the U.S. for previously treated patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). 
  • Related Content: Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer.
  • In a post-hoc analysis of 40 patients, Lumakras achieved a 77.5% disease control rate (DCR), similar to patients without brain metastases.
  • A median progression-free survival (PFS) of 5.3 months and median overall survival (OS) of 8.3 months were observed.
  • In patients evaluable by Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, 14 of 16 patients (88%) maintained intracranial disease control of their stable brain lesions during Lumakras therapy with two achieving complete responses of non-target lesions. 
  • The safety profile of Lumakras in the brain metastases group was consistent with previous reports.
  • Amgen is enrolling patients with active brain metastases in an arm of the CodeBreaK 101 study.
  • Price Action: AMGN stock is down 0.41% at $219.97 during the premarket session on the last check Thursday.

Related Articles (AMGN)

View Comments and Join the Discussion!

Posted-In: Briefs Non-Small Cell Lung Cancer Phase 2 TrialBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at